Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

68.20 +0.02 (+0.03%)
Official Closing Price Updated: 4:10 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,400,134
Open 68.38
Bid (Size) 68.07 (1)
Ask (Size) 68.20 (1)
Prev. Close 68.18
Today's Range 67.99 - 68.53
52wk Range 65.28 - 81.44
Shares Outstanding 2,222,113,553
Dividend Yield 2.87%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bristol Myers' Flagship Opdivo Shows Long Term Durable Benefits In Lung Cancer Patients
 
Via Benzinga
Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies
 
Via Benzinga

Performance

YTD
-5.62%
-5.62%
1 Month
-2.56%
-2.56%
3 Month
-5.26%
-5.26%
6 Month
-5.36%
-5.36%
1 Year
-6.87%
-6.87%

More News

Read More
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 Trial
From Bristol Myers Squibb
Via Business Wire
AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners
Via Benzinga
How Is The Market Feeling About Bristol-Myers Squibb?
Via Benzinga
Where Bristol-Myers Squibb Stands With Analysts
Via Benzinga
Could This Drug Candidate Be a Winner for These 2 Big Pharma Stocks?
Via The Motley Fool
Is Eli Lilly or Bristol Myers Squibb the Better Value Stock to Buy Right Now?
Via The Motley Fool
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
BioNTech Is Ripe For A Rebound In 2023
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via TheNewswire.com
Exposures Product Safety
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via News Direct
Exposures Product Safety
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via Benzinga
These Are The Top 3 Large Caps For Yield And Dividend Growth
Via MarketBeat
Topics Economy
Exposures Interest Rates
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says
Via Benzinga
Wall Street Is Bullish on GE HealthCare as It Invests in AI
Via The Motley Fool
4 Top Value Stock ETFs for Long-Term Wealth Building
Via The Motley Fool
2 Top Healthcare Stocks to Buy for the Long Haul
Via The Motley Fool
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
Via Investor's Business Daily
Got $5,000? These 2 High-Yielding Dividend Stocks Are Near Their 52-Week Lows
Via The Motley Fool
Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments
From Bristol Myers Squibb
Via Business Wire
Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation
Via Benzinga
Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023
From Bristol Myers Squibb
Via Business Wire
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.